Skip to main content

Table 2 Results of human magnetic luminex assay

From: Coronary microvascular dysfunction is associated with degree of anaemia in end‐stage renal disease

Assay

CFVR < 2 (n = 6)

CFVR ≥ 2 (n = 15)

p value

Angiopoetin-2 (pg/ml)

3274 (1000–5136)

3051 (2230–4053)

0.850

Atrial natriuretic peptide (pg/ml)

25,836 ± 9520

20,568 ± 11,210

0.329

Detectable KIM-1 n (%)

2 (33)

5 (31)

1.0

Galectin-3 (ng/ml)

1.3 (1-1.3)

1.3 (1-1.4)

0.791

IL-1ra (pg/ml)

667 (526–742)

515 (384–729)

0.850

IL-6 (pg/ml)

2.09 ± 1.3

2.69 ± 1.35

0.371

IL-8 (pg/ml)

6.1 (4.2–11.5)

11.4 (8–23)

0.132

IL-10 (pg/ml)

2.5 (0.9–4.1)

1.4 (0.9–3.4)

1.0

Leptin (ng/ml)

17.7 (6.6–20.6)

13.2 (4.2–50.4)

0.910

MCP-1 (pg/ml)

396 ± 221

375 ± 102

0.770

MMP-9 (pg/ml)

10,614 (4955–11,509)

9880 (6244–13,648)

1.0

NGAL (ng/ml)

26.3 ± 8.9

26.6 ± 4.8

0.898

ST2 (ng/ml)

14 (10–33)

12 (9–19)

0.850

TNF\({\upalpha }\) (pg/ml)

6.1 (4.5–8.1)

5.7 (5.1–6.7)

0.850

Uromodulin (ng/ml)

18 ± 9

21 ± 10

0.53

VEGF (pg/ml)

52 ± 26

75 ± 25

0.108

  1. Data are presented as mean ± SD or median (IQR)
  2. CFVR, coronary flow velocity reserve; KIM-1, kidney injury molecule 1; IL-1ra, interleukin 1 receptor antagonist; IL-6, interleukin-6; IL-8, interleukin-8; IL-10, interleukin-10; MCP-1, monocyte chemoattractant protein; MMP-9, matrix metallopeptidase 9; NGAL, neutrophil gelatinase associated lipocalin; ST2, suppression of tumorigenicity 2; TNFα, tumour necrosis factor alpha; VEGF, vascular endothelial growth factor.